BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 30367559)

  • 1. Single-cell RNA-seq analysis reveals the platinum resistance gene COX7B and the surrogate marker CD63.
    Tanaka N; Katayama S; Reddy A; Nishimura K; Niwa N; Hongo H; Ogihara K; Kosaka T; Mizuno R; Kikuchi E; Mikami S; Miyakawa A; Arenas E; Kere J; Oya M; Uhlén P
    Cancer Med; 2018 Dec; 7(12):6193-6204. PubMed ID: 30367559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TNFAIP2 expression induces epithelial-to-mesenchymal transition and confers platinum resistance in urothelial cancer cells.
    Niwa N; Tanaka N; Hongo H; Miyazaki Y; Takamatsu K; Mizuno R; Kikuchi E; Mikami S; Kosaka T; Oya M
    Lab Invest; 2019 Nov; 99(11):1702-1713. PubMed ID: 31263157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transcribed ultraconserved region Uc.63+ promotes resistance to cisplatin through regulation of androgen receptor signaling in bladder cancer.
    Sekino Y; Sakamoto N; Ishikawa A; Honma R; Shigematsu Y; Hayashi T; Sentani K; Oue N; Teishima J; Matsubara A; Yasui W
    Oncol Rep; 2019 May; 41(5):3111-3118. PubMed ID: 30864720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multilayered Omics-Based Analysis of a Head and Neck Cancer Model of Cisplatin Resistance Reveals Intratumoral Heterogeneity and Treatment-Induced Clonal Selection.
    Niehr F; Eder T; Pilz T; Konschak R; Treue D; Klauschen F; Bockmayr M; Türkmen S; Jöhrens K; Budach V; Tinhofer I
    Clin Cancer Res; 2018 Jan; 24(1):158-168. PubMed ID: 29061642
    [No Abstract]   [Full Text] [Related]  

  • 5. Single-cell RNA sequencing reveals the tumor microenvironment and facilitates strategic choices to circumvent treatment failure in a chemorefractory bladder cancer patient.
    Lee HW; Chung W; Lee HO; Jeong DE; Jo A; Lim JE; Hong JH; Nam DH; Jeong BC; Park SH; Joo KM; Park WY
    Genome Med; 2020 May; 12(1):47. PubMed ID: 32460812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Whole-genome CRISPR Screen Identifies a Role of MSH2 in Cisplatin-mediated Cell Death in Muscle-invasive Bladder Cancer.
    Goodspeed A; Jean A; Costello JC
    Eur Urol; 2019 Feb; 75(2):242-250. PubMed ID: 30414698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repression of GRIM19 expression potentiates cisplatin chemoresistance in advanced bladder cancer cells via disrupting ubiquitination-mediated Bcl-xL degradation.
    Ni F; Yan CY; Zhou S; Hui PY; Du YH; Zheng L; Yu J; Hu XJ; Zhang ZG
    Cancer Chemother Pharmacol; 2018 Oct; 82(4):593-605. PubMed ID: 30032449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancement of sensitivity of urinary bladder tumor cells to cisplatin by c-myc antisense oligonucleotide.
    Mizutani Y; Fukumoto M; Bonavida B; Yoshida O
    Cancer; 1994 Nov; 74(9):2546-54. PubMed ID: 7923012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations.
    Gao J; Meng Q; Zhao Y; Chen X; Cai L
    BMC Cancer; 2016 Jul; 16():470. PubMed ID: 27411790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-cell transcriptome analysis reveals the association between histone lactylation and cisplatin resistance in bladder cancer.
    Li F; Zhang H; Huang Y; Li D; Zheng Z; Xie K; Cao C; Wang Q; Zhao X; Huang Z; Chen S; Chen H; Fan Q; Deng F; Hou L; Deng X; Tan W
    Drug Resist Updat; 2024 Mar; 73():101059. PubMed ID: 38295753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA Methylation of miR-7 is a Mechanism Involved in Platinum Response through
    Vera O; Jimenez J; Pernia O; Rodriguez-Antolin C; Rodriguez C; Sanchez Cabo F; Soto J; Rosas R; Lopez-Magallon S; Esteban Rodriguez I; Dopazo A; Rojo F; Belda C; Alvarez R; Valentin J; Benitez J; Perona R; De Castro J; Ibanez de Caceres I
    Theranostics; 2017; 7(17):4118-4134. PubMed ID: 29158814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Organic cation transporter OCT6 mediates cisplatin uptake and resistance to cisplatin in lung cancer.
    Kunii E; Oguri T; Kasai D; Ozasa H; Uemura T; Takakuwa O; Ohkubo H; Takemura M; Maeno K; Niimi A
    Cancer Chemother Pharmacol; 2015 May; 75(5):985-91. PubMed ID: 25772757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GSTP1 determines cis-platinum cytotoxicity in gastric adenocarcinoma MGC803 cells: regulation by promoter methylation and extracellular regulated kinase signaling.
    Zhang Y; Qu X; Jing W; Hu X; Yang X; Hou K; Teng Y; Zhang J; Liu Y
    Anticancer Drugs; 2009 Mar; 20(3):208-14. PubMed ID: 19396019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitizing effect of galectin-7 in urothelial cancer to cisplatin through the accumulation of intracellular reactive oxygen species.
    Matsui Y; Ueda S; Watanabe J; Kuwabara I; Ogawa O; Nishiyama H
    Cancer Res; 2007 Feb; 67(3):1212-20. PubMed ID: 17283157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intracellular uptake of an antitumor-active azole-bridged dinuclear platinum(II) complex in cisplatin-resistant tumor cells.
    Kishimoto S; Yasuda M; Suzuki R; Fukushima S
    Biometals; 2016 Dec; 29(6):1075-1083. PubMed ID: 27787693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adenovirus-mediated LRIG1 expression enhances the chemosensitivity of bladder cancer cells to cisplatin.
    Yan Z; Jiang J; Li F; Yang W; Xie G; Zhou C; Xia S; Cheng Y
    Oncol Rep; 2015 Apr; 33(4):1791-8. PubMed ID: 25695283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A systems biology approach to identify microRNAs contributing to cisplatin resistance in human ovarian cancer cells.
    Liu W; Wang S; Zhou S; Yang F; Jiang W; Zhang Q; Wang L
    Mol Biosyst; 2017 Oct; 13(11):2268-2276. PubMed ID: 28861582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NPEPPS Is a Druggable Driver of Platinum Resistance.
    Jones RT; Scholtes M; Goodspeed A; Akbarzadeh M; Mohapatra S; Feldman LE; Vekony H; Jean A; Tilton CB; Orman MV; Romal S; Deiter C; Kan TW; Xander N; Araki SP; Joshi M; Javaid M; Clambey ET; Layer R; Laajala TD; Parker SJ; Mahmoudi T; Zuiverloon TCM; Theodorescu D; Costello JC
    Cancer Res; 2024 May; 84(10):1699-1718. PubMed ID: 38535994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxaliplatin in treatment of the cisplatin-resistant MKN45 cell line of gastric cancer.
    Tozawa K; Oshima T; Kobayashi T; Yamamoto N; Hayashi C; Matsumoto T; Miwa H
    Anticancer Res; 2008; 28(4B):2087-92. PubMed ID: 18751380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LncRNA UCA1 promotes proliferation and cisplatin resistance of oral squamous cell carcinoma by sunppressing miR-184 expression.
    Fang Z; Zhao J; Xie W; Sun Q; Wang H; Qiao B
    Cancer Med; 2017 Dec; 6(12):2897-2908. PubMed ID: 29125238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.